Syneos Health nomme Michael Bonello au poste de directeur financier

Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research Industry

MORRISVILLE, N.C., mai 2, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as Chief Financial Officer, effective juillet 1, 2023. Stanford (Ben) Rudnick will continue to serve as Interim Chief Financial Officer until that time.

Mr. Bonello has more than 30 years of financial leadership experience, including 15 years in the clinical research industry. He most recently served as Chief Financial Officer of Clario, Inc., a clinical trial data collection company, since 2021. From 2008 to 2021, Mr. Bonello held roles of increasing responsibility at Nasdaq-listed PRA Health Sciences, Inc., including Executive Vice President and Chief Financial Officer from 2018 through the company’s sale to ICON plc, and previously as Senior Vice President, Accounting and Corporate Controller from 2008 to 2018. Plus tôt dans sa carrière, il a occupé des postes de direction financière chez Cree, Inc. et Genworth Financial, et il a été cadre supérieur dans le domaine de l’audit chez PricewaterhouseCoopers LLP. Mr. Bonello is a certified public accountant.

“With decades of relevant finance expertise – and significant clinical research industry experience – Mike is ideally suited to serve as our next Chief Financial Officer. As we further transform Syneos Health for the technology and data-powered future of clinical development and commercialization, I look forward to working with Mike and our entire team to execute on our growth, innovation and efficiency goals,” said Michelle Keefe, CEO of Syneos Health.  

“Syneos Health is well regarded for its integrated strategy and leading solutions supporting customers’ development and commercialization objectives,” Mr. Bonello said. “I am excited to partner with Michelle, the rest of the management team and the talented employees across the organization to drive growth and value for all stakeholders.”

About Michael Bonello

Mr. Bonello previously served as the Chief Financial Officer of Clario, Inc., a clinical trial data collection company, from November 2021 to present. Prior to that role, from May 2018 to August 2021, he served as Executive Vice President and Chief Financial Officer of PRA Health Sciences, Inc. (“PRA”), a former contract research organization that was acquired by ICON plc in 2021. Mr. Bonello previously served as Senior Vice President, Accounting and Corporate Controller for PRA, after having joined the company in March 2008. Prior to PRA, Mr. Bonello held positions with Cree, Inc., where he was Director of Finance/Corporate Controller, and Genworth Financial (formerly GE Mortgage Insurance Corporation) where he served as Vice President, Domestic Controller and Global Reporting Leader. Mr. Bonello also served for seven years in the audit practice at PricewaterhouseCoopers LLP. He received a B.B.A. with a concentration in accounting from St. Bonaventure University.

About Syneos Health

Syneos Health^® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. Nous traduisons des perspectives cliniques, d’affaires médicales et commerciales uniques en résultats qui répondent aux réalités du marché actuel.

Nous réunissons une équipe de professionnels talentueux qui travaillent dans plus de 110 pays et qui ont une connaissance approfondie des comportements des patients et des médecins, ainsi que de la dynamique du marché.

Ensemble, nous partageons des connaissances, utilisons les dernières technologies et appliquons des pratiques commerciales de pointe pour accélérer la livraison d’importants traitements par nos clients aux patients.

Syneos Health soutient une culture diversifiée, équitable et inclusive qui prend soin des collègues, des clients, des patients, des collectivités et de l’environnement.

To learn more about how we are Shortening the distance from lab to life^®, visit syneoshealth.com or subscribe to our podcast.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statement’s regarding our future financial results, transformation efforts and strategy. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: the Company’s potential failure to generate a large number of new business awards and the risk of delay, termination, reduction in scope, or failure to go to contract of our business awards; the Company’s potential failure to convert backlog to revenue; fluctuations in the Company’s operating results and effective income tax rate; and other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended décembre 31, 2022 as updated by the Company’s other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Relations Contact:  Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 [email protected]

Media Contact: Gary Gatyas Executive Director, External Communications +1 908 763 3428  [email protected]